Chennai: On Thursday, The phase-1 clinical trials of Covaxin, India’s first indigenous covid-19 vaccine began in SRM Medical College Hospital and Research Centre in Chennai.

Trials have also been initiated in several other places including Delhi Goa Patna amongst other places.

SRM is one of 12 medical institutions across India that will carry out the trial of COVAXIN, the indigenous coronavirus vaccine to test the suitability of vaccine for public health use which is developed by Hyderabad’s Bharat Biotech in collaboration with ICMR.

The principal investigator of the clinical trials of the hospital Dr. Satyajit Mohapatra confirmed the commencement of the human trials.

Earlier, it was said that 15th August was the date, the ICMR  wanted to launch the vaccine for public use and advised the institution to Fast Track  approval for clinical trial and ensure that the subject enrolment was initiated no later than July 7.

On a website of Bharat Biotech it is said that “the vaccine received the DCGI approval for phase1 and 2 human clinical trials and the trials will commence across India from July 2020.”

SRM research and development centre was earlier engaged in clinic and medical trials for the vaccine of virus named Rotavirus, they involved and administered for the protection and precautions against Rotavirus infection which caused severe diarrhoea and pentavalent vaccine, administered to protect and keep healthy the childrens from five diseases including hepatitis B and diphtheria, pertussis and tetanus.